DrugPatentWatch Database Preview
Details for Patent: 9,074,256
Email this page to a colleague
Which drugs does patent 9,074,256 protect, and when does it expire?
Patent 9,074,256 protects FANAPT and is included in one NDA.
This patent has five patent family members in four countries.
Summary for Patent: 9,074,256
| Title: | Method of predicting a predisposition to QT prolongation |
| Abstract: | The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. |
| Inventor(s): | Lavedan; Christian (Potomac, MD), Volpi; Simona (Derwood, MD), Licamele; Louis (Potomac, MD) |
| Assignee: | Vanda Pharmaceuticals, Inc. (Washington, DC) |
| Application Number: | 13/263,076 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,074,256
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-001 | May 6, 2009 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Try it Free | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-002 | May 6, 2009 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Try it Free | ||||
| Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-003 | May 6, 2009 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | ⤷ Try it Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,074,256
| PCT Information | |||
| PCT Filed | April 05, 2010 | PCT Application Number: | PCT/US2010/029943 |
| PCT Publication Date: | October 14, 2010 | PCT Publication Number: | WO2010/117941 |
International Family Members for US Patent 9,074,256
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2757723 | ⤷ Try it Free | |||
| European Patent Office | 2416778 | ⤷ Try it Free | |||
| Japan | 2012522534 | ⤷ Try it Free | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
